Partners & Business Development
Cempra is focused on the clinical development of its two lead anti-infective candidates, TAKSTA and CEM-101. TAKSTA (sodium fusidate, CEM-102) is currently in a Phase II/III adaptive design non-inferiority clinical trial versus linezolid for the treatment of acute bacterial skin and skin structure infections, including those caused by methicillin-resistant S. aureus (MRSA). This study is projected to be completed by Q4 2010.
CEM-101 is a novel, potent, orally-active fluoroketolide with a broad spectrum of activity against S. pneumoniae, including macrolide-resistant strains, atypical bacteria such as Mycoplasma and Legionella, M. avium, biodefense-relevant pathogens and Plasmodium falciparum. Phase II clinical trials in moderate-to-moderately severe community-acquired bacterial pneumonia will begin in early 2010.
CEM-101 was selected from a library of over 500 macrolides licensed from Optimer Pharmaceuticals.
In addition to CEM-101, promising lead candidates for treating anti-inflammatory diseases, such as chronic obstructive pulmonary disease (COPD), late stage asthma and psoriasis, endocrine diseases and gastrointestinal motility disorders have also been identified and are available for partnering.
To explore business opportunities with Cempra, please contact:
Angela Marrow
(919) 467-1716
amarrow@cempra.com
Cempra is focused on the clinical development of its two lead anti-infective candidates, TAKSTA and CEM-101. TAKSTA (sodium fusidate, CEM-102) is currently in a Phase II/III adaptive design non-inferiority clinical trial versus linezolid for the treatment of acute bacterial skin and skin structure infections, including those caused by methicillin-resistant S. aureus (MRSA). This study is projected to be completed by Q4 2010.
CEM-101 is a novel, potent, orally-active fluoroketolide with a broad spectrum of activity against S. pneumoniae, including macrolide-resistant strains, atypical bacteria such as Mycoplasma and Legionella, M. avium, biodefense-relevant pathogens and Plasmodium falciparum. Phase II clinical trials in moderate-to-moderately severe community-acquired bacterial pneumonia will begin in early 2010.
CEM-101 was selected from a library of over 500 macrolides licensed from Optimer Pharmaceuticals.
In addition to CEM-101, promising lead candidates for treating anti-inflammatory diseases, such as chronic obstructive pulmonary disease (COPD), late stage asthma and psoriasis, endocrine diseases and gastrointestinal motility disorders have also been identified and are available for partnering.
To explore business opportunities with Cempra, please contact:
Angela Marrow
(919) 467-1716
amarrow@cempra.com